SNFGE SNFGE
 
Thématique :
- Cancers autres (hors CCR et CHC)
Originalité :
Très original
Solidité :
Très solide
Doit faire évoluer notre pratique :
Dans certains cas
 
 
Nom du veilleur :
Professeur Sylvain MANFREDI
Coup de coeur :
 
 
Digestive and Liver Disease
  2017/03  
 
  2017 Mar;49(3):291-296  
  doi: 10.1016/j.dld.2016.12.004  
 
  Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country  
 
  Lahner E, Hassan C, Esposito G, Carabotti M, Zullo A, Dinis-Ribeiro M, Annibale B  
  https://www.ncbi.nlm.nih.gov/pubmed/28034664  
 
 

Abstract

BACKGROUND:

Atrophic gastritis (AG) is at increased risk of gastric neoplasia, thus surveillance gastroscopy has been proposed.

AIMS:

To assess cost of detecting gastric neoplasias by surveillance endoscopy according to identified risk factors in Italy.

METHODS:

Post-hoc analysis of a cohort study including 200 AG-patients from Italy followed up for a mean of 7.5 (4-23.4) years was done. Considered risk factors were: age >50years, extensive atrophy, pernicious anaemia, OLGA-OLGIM scores 3-4 at diagnosis. The number of 4-year-surveillance endoscopies needed to be performed to detect one gastric neoplasia (NNS) was calculated.

RESULTS:

In 19 patients neoplasias (4 gastric cancers, 8 type 1 gastric carcinoids, 7 dysplasias) were detected at the 361 surveillance gastroscopies, corresponding to NNS of 19 and a cost per gastric neoplastic lesion of €2945. By restricting surveillance to pernicious anaemia patients, reduction of NNS and cost per neoplasia to 13.8 and €2139 may be obtained still detecting 74% of neoplasias. By limiting the surveillance to pernicious anaemia patients and OLGA 3-4, 5 (26.3%) neoplasias would have been detected with a corresponding NNS of 5.4 and a cost per lesion of €837.

CONCLUSION:

Risk factors may allow an efficient allocation of financial and medical resources for endoscopic surveillance in AG in a low risk country.

 
Question posée
 
La surveillance endoscopique des gastrites atrophiques est-elle coût-efficace ?
 
Question posée
 
La surveillance endoscopique tous les 4 ans des gastrites atrophiques est coût-efficace surtout chez les sujets avec anémie ferriprive.
 
Commentaires

-

 
www.snfge.org